LYELL IMMUNOPHARMA INC (LYEL) competitors & alternatives
Health Care · NASDAQ
LYELL IMMUNOPHARMA INC (LYEL)'s top competitors and alternatives — its most similar public companies — include CRISPR THERAPEUTICS AG (CRSP), ALLOGENE THERAPEUTICS INC (ALLO), Bristol Myers Squibb (BMY), IMMUNITYBIO INC (IBRX), VIR BIOTECHNOLOGY INC (VIR), CANDEL THERAPEUTICS INC (CADL), NEKTAR THERAPEUTICS (NKTR), CYTOMX THERAPEUTICS INC (CTMX), Genelux Corp (GNLX), Indaptus Therapeutics, Inc. (INDP), AGENUS INC (AGEN) and CARIBOU BIOSCIENCES INC (CRBU). These are LYELL IMMUNOPHARMA INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top LYEL competitors & alternatives
-
CRISPR THERAPEUTICS AGCRSPHealth Care
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and…
$47.24 (as of 2026-07-22) · market cap $4.6B
-
ALLOGENE THERAPEUTICS INCALLOHealth Care
Allogene Therapeutics is pioneering off-the-shelf, donor-derived CAR T cell therapies to provide more scalable and accessible cancer and autoimmune disease…
$1.86 (as of 2026-07-22) · market cap $637M
-
Bristol Myers SquibbBMYHealth Care
Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse…
$60.76 (as of 2026-07-22) · market cap $124.9B
-
IMMUNITYBIO INCIBRXHealth Care
ImmunityBio develops engineered natural killer cell and cancer vaccine therapies, led by its approved ANKTIVA treatment for bladder and lung cancers, to…
$7.51 (as of 2026-07-22) · market cap $8.0B
-
VIR BIOTECHNOLOGY INCVIRHealth Care
Vir Biotechnology develops novel immunology-driven therapeutics targeting infectious diseases and cancer using proprietary T-cell engagement and masking…
$9.35 (as of 2026-07-22) · market cap $1.6B
-
CANDEL THERAPEUTICS INCCADLHealth Care
Clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies to trigger systemic anti-tumor immune responses by inducing immunogenic…
$10.09 (as of 2026-07-22) · market cap $739M
-
NEKTAR THERAPEUTICSNKTRHealth Care
A clinical-stage biotechnology company developing next-generation immunomodulatory therapies for autoimmune diseases and cancer.
$69.32 (as of 2026-07-22) · market cap $2.4B
-
CYTOMX THERAPEUTICS INCCTMXHealth Care
CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity,…
$3.33 (as of 2026-07-22) · market cap $724M
-
Genelux CorpGNLXHealth Care
Genelux is a late clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies designed to selectively kill tumor cells and…
$2.96 (as of 2026-07-22) · market cap $131M
-
Indaptus Therapeutics, Inc.INDPHealth Care
A clinical-stage biotechnology company currently evaluating strategic options and potential business combinations to maximize shareholder value.
$2.64 (as of 2026-07-22) · market cap $300M
-
AGENUS INCAGENHealth Care
A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term…
$5.53 (as of 2026-07-22) · market cap $232M
-
CARIBOU BIOSCIENCES INCCRBUHealth Care
Caribou develops off-the-shelf CRISPR-engineered CAR-T cell therapies designed to make cellular immunotherapy faster, cheaper, and accessible to more blood…
$1.66 (as of 2026-07-22) · market cap $165M
Not quite? Describe exactly what you want →
Peers are LYELL IMMUNOPHARMA INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: LYELL IMMUNOPHARMA INC (LYEL).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.